REG - Proteome Sciences - AGM Statement

Proteome SciencesAnnouncement

Yesterday 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250516:nRSP9209Ia&default-theme=true

RNS Number : 9209I  Proteome Sciences PLC  16 May 2025

 16 May 2025

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Annual General Meeting Statement

 

At the Company's Annual General Meeting ("AGM") being held today at 12.00
noon, the Chairman, Christopher Pearce, will make the following statement:

 

"The recovery from the global challenges affecting the pharmaceutical and
biotech markets in the second half of 2024 has continued in 2025.  Following
the announcement in February of the major services contract with a US pharma
the pipeline of orders continues to expand now extending well into 2026 with a
similar trend at our San Diego facility with eight projects ongoing. It is too
early to establish whether the recent tariff changes by the US Government
could affect TMT reagent revenues, but any impact is likely to be short lived.
We continue to positively progress licensing discussions for our new DXT tags
for multiplexing DIA which we are excited to be presenting in June at the
American Society for Mass Spectrometry ("ASMS") in Baltimore. After completing
our first commercial single cell proteomics ("SCP") project in January, we are
discussing a follow up order with the same customer with other SCP projects
ongoing. The extra capacity from the two additional mass spectrometry systems
installed at our main Frankfurt site are working at full capacity to meet the
increased level of orders in our services business.  After considerable
increases in customer orders and services, demand for our proteomics business
has rebounded strongly and we are optimistic that it is well positioned to
deliver substantial future increases in revenue and returns."

 

 

For further information:

 Proteome Sciences plc
 Christopher Pearce, Executive Chairman                                  Tel: +44 (0)20 7043 2116
 Dr. Ian Pike, Chief Scientific Officer
 Richard Dennis, Chief Commercial Officer

 Allenby Capital Limited (Nominated Adviser & Broker)
 John Depasquale / Lauren Wright (Corporate Finance)                     Tel: +44 (0) 20 3328 5656

 Tony Quirke / Stefano Aquilino (Equity Sales & Corporate Broking)

 

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com/)
)

 

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and
contextualising new targets and defining mechanisms of biological activity,
while analysis using Super-Depletion and TMTcalibrator™ provides access to
over 8,500 circulating plasma proteins for the discovery of disease-related
biomarkers. Targeted assay development using mass spectrometry delivers high
sensitivity, interference-free biomarker analyses in situations where standard
ELISA assays are not available.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMAAMLTMTTBBMA